This drug target was first discovered on the basis of damaging variants in the PCSK9 gene that reduced circulating low-density lipoprotein (LDL) cholesterol levels and reduced the risk of CAD (Cohen et al., 2006). This evidence concerns the gene PCSK9 and coronary artery disorder.